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Hypoalbuminemia increases lysophosphatidylcholine in low- Elevated plasma levels of low-density lipoprotein
density lipoprotein of normocholesterolemic subjects. (LDL) have been associated with the development of
Background. A phospholipid, lysophosphatidylcholine (LPC), atherosclerosis [1]. The interphase between these condi-
is the major determinant of the atherosclerotic properties of tions is considered to be oxidation of LDL in the arteryoxidized low-density lipoprotein (LDL). Under normal circum-
wall [2]. During this process of oxidation phosphatidyl-stances most LPC is bound to albumin. We hypothesized that
choline is extensively hydrolyzed to lysophosphatidyl-lipoprotein LPC concentrations are increased in hypoalbumi-
choline (LPC) by a phospholipase A2 called platelet-nemic patients with the nephrotic syndrome, irrespective of
their lipid levels. To test this hypothesis, we selected nephrotic activating factor acetylhydrolase that exists in plasma
and control subjects with matched LDL cholesterol levels. largely in association with LDL [3–5]. LPC is present in
Methods. Lipoproteins and the albumin-rich lipoprotein- a concentration of about 500 nmol/mg protein in oxidized
deficient fractions were separated by ultracentrifugation and LDL, whereas in native LDL derived from healthy sub-their phospholipid composition was analyzed by thin-layer
jects concentrations of only 25 nmol/mg protein havechromatography.
been found [6, 7]. Lysophosphatidylcholine has beenResults. Nephrotic subjects (albumin 23 6 2 g/liter and LDL
proposed as an important determinant of the atheroscle-cholesterol 3.1 6 0.2 mmol/liter) had a LDL LPC concentration
that was increased (P , 0.05) to 66 6 7 vs. 35 6 6 mmol/ rotic properties of oxidized LDL [8], although it should
liter in matched controls (albumin 42 6 5 g/liter and LDL be noted that many other chemical changes are induced
cholesterol 3.1 6 0.2 mmol/liter). LPC in very low-density by oxidation which also contribute to the biological ef-
lipoprotein plus intermediate-density lipoprotein (VLDL 1
fects of oxidized LDL [8, 9]. Impairment of endothelialIDL) in these subjects was also increased to 33 6 7 vs. 9 6 2
reactivity, caused by oxidized LDL in vitro, was abol-mmol/liter in controls (P , 0.05). Conversely, LPC was de-
ished by LPC depletion [10]. Other effects of LPC oncreased to 19 6 4 mmol/liter in the albumin-containing fraction
of these hypoalbuminemic patients, as compared to 46 6 10 the endothelium include superoxide production [11–13],
mmol/liter in the controls (P , 0.05). LPC was also low (14 6 activation of protein kinase C [11, 14, 15], and increased
4 mmol/liter) in the albumin-containing fraction of hypoalbumi- expression of leukocyte adhesion molecules [7]. Some
nemic, hypocholesterolemic patients with nonrenal diseases. increases in LDL LPC content have been identified inIn hyperlipidemic nephrotic subjects (albumin 21 6 2 g/liter
patients with dyslipidemia due to diabetes [16, 17], orand LDL cholesterol 5.7 6 0.5 mmol/liter) the LPC levels in
familial hypercholesterolemia [18]. However, whetherLDL and VLDL 1 IDL were further increased, to 95 6 20
increased LPC levels can occur in circulating LDL inand 56 6 23 mmol/liter, respectively (P , 0.05).
Conclusion. These findings suggest that in the presence of normolipidemic patients and whether this is associated
hypoalbuminemia in combination with proteinuria, LPC shifts with detrimental effects is unknown.
from albumin to VLDL, IDL and LDL. This effect is indepen- Approximately 10% of total human plasma phospho-
dent of hyperlipidemia. Increased LPC in lipoproteins may be
lipid consists of LPC [17, 19–21]. About 80% of this LPCan important factor in the disproportionate increase in cardio-
[20] is tightly bound to albumin [19, 22]. However, on avascular disease in nephrotic patients with hypoalbuminemia.
molar basis the capacity and affinity for LPC is much
higher for LDL than for albumin [23]. Indeed, studies
with both nephrotic and analbuminemic rats with dyslipi-Key words: hypoalbuminemia, atherosclerosis, nephrotic syndrome,
proteinuria, hyperlipidemia. demia demonstrated that most of the LPC normally
bound to albumin was shifted to lipoproteins [24]. IfReceived for publication February 17, 1998
increased LPC levels in circulating LDL have adverseand in revised form September 22, 1998
Accepted for publication September 22, 1998 effects, insight into the separate effects of hyperlipidemia
and hypoalbuminemia on the distribution of LPC in lipo- 1999 by the International Society of Nephrology
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Table 1. Clinical characteristics
NS-H NS-N CON NRD SNA
Sex (M/F) 7/1 6/1 6/0 4/4 4/2
Age years 42 (25–57) 46 (24–57) 32 (25–50) 52 (17–79) 41 (22–60)
Total protein g/liter 47.662.9a 55.161.4a 66.062.8 52.3 63.3a 55.763.3a
Albumin g/liter 20.761.9b 23.261.5b 42.164.7 24.2 61.1b 29.161.0b
Cholesterol mmol /liter 10.0561.64a 5.4660.58 4.95 60.27 3.18 60.30a 6.6860.89
Phosphoipids mmol /liter 4.2860.56b 2.7460.20 2.52 60.09 2.28 60.20 3.17 60.39
Triglycerides mmol /liter 3.661.0a 2.160.5 1.5 60.3 1.8 60.4 1.7 60.3
Creatinine lmol /liter 78.569.5 114.7623.0 81.7 67.6 75.1 613.0 110.7616.2
Proteinuria g/day 6 (2–7) 8 (1–16) ND ND 7 (2–10)
Data are means 6 sem, except for age and proteinuria which are presented as median and range. Abbreviations are: NS-H, hyperlipidemic nephrotic syndrome;
NS-N, normolipidemic nephrotic syndrome; CON, control subjects; NRD, non-renal diseases; SNA, sub-normal albumin; ND, not determined.
a P , 0.05 vs. control
b P , 0.01 vs. control
proteins will have important implications for therapeutic Crohn’s disease with protein depletion, one acute respira-
strategies. In hyperlipidemic patients with the nephrotic tory distress syndrome in association with multiple my-
syndrome we found increased LPC in LDL, in compari- eloma, one neuromuscular disease, one hemihepatectomy
son to controls with normal lipid and albumin levels after an isolated metastasis, and one sepsis with perforated
[21]. However, it is not clear whether this was due to diverticulitis. Of the SNA patients, one had membranous
hyperlipidemia or hypoalbuminemia. glomerulopathy, one focal segmental glomerulosclerosis,
To test the hypothesis that lipoprotein LPC concentra- one minimal change lesion, one mesangioproliferative
tions are increased in hypoalbuminemic patients irre- glomerulonephritis, and two IgA-nephritis.
spective of their lipid levels, we utilized larger groups of
Protocolsubjects to select nephrotic and control subjects with
matched total plasma phospholipid and LDL cholesterol Blood was collected, after an overnight fast, in chilled
levels. Furthermore, we also studied patients with low K-EDTA coated tubes and immediately centrifuged at
albumin as well as low cholesterol levels due to nonrenal 48C for 10 minutes at 1000 3 g. Lipoproteins were iso-
diseases. lated from fresh plasma. The study protocol was ap-
proved by the Utrecht University Hospital Ethics Com-
mittee for study in human beings. Patients and subjectsMETHODS
gave written informed consent after explanation of theSubjects
protocol.
Lipoprotein composition was measured in five groups.
Three groups were formed from a cohort of 21 hypoal- Laboratory parameters
buminemic patients with renal disease: a group of pa-
Albumin, creatinine, cholesterol, phospholipid, and tri-tients with hyperlipidemic nephrotic syndrome (NS-H,
glyceride determination. Plasma albumin was determinedN 5 8), a group with normolipidemic nephrotic syn-
by immuno-electrophoresis. Standard dye-binding meth-drome (NS-N, N 5 7), and a group with subnormal
ods tend to overestimate albumin concentrations duringalbumin (SNA, N 5 6). We also studied patients with
hypoalbuminemia because of aspecific binding to globu-nonrenal diseases (NRD, N 5 8), and healthy controls
lins [25]. Plasma creatinine was determined colorimetri-(CON, N 5 6). The inclusion criteria were: for the NS
cally. Cholesterol, triglyceride (Boehringer GmbH,patients, plasma albumin , 26 g/liter; NRD patients,
Mannheim, Germany) and phospholipid (bioMe´rieux,plasma albumin , 30 g/liter; SNA patients, plasma albu-
Marcy-l’Etoile, France) concentrations were assayed en-min 26–35 g/liter; and CON, plasma albumin . 35 g/liter
zymatically.and total phospholipids and LDL cholesterol matched
Lipoprotein isolation by density-gradient ultracentrifu-to the NS-N. The latter were selected from a large group
gation. Plasma lipoproteins and the albumin-rich lipo-of healthy controls. Clinical characteristics are summa-
protein-deficient fractions were separated by density-rized in Table 1. The histologic diagnosis of patients with
gradient ultracentrifugation into four fractions: very low-NS-H was membranous glomerulophathy (N 5 4), and
density lipoprotein (VLDL) plus intermediate-densityminimal lesions (N 5 4). Of the NS-N patients five had
lipoprotein (IDL), density (d) , 1.019 g/ml; low-densitymembranous glomerulopathy, one chronic transplanta-
lipoprotein (LDL), d 1.019 to 1.063; high-density lipopro-tion nephropathy, and one had minimal lesions. Of the
tein, HDL, d 1.063 to 1.21 g/ml and lipoprotein-deficientNRD patients one had short bowel syndrome, one pan-
creas necrosis, one liver cirrhosis and pancreatitis, one plasma (LDP) with a d . 1.21 g/ml) [24].
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Table 2. Lipoprotein cholesterol (mmol/liter)
NS-H NS-N CON NRD SNA
N 8 7 6 8 6
VLDL 1 IDL 2.4160.85a 1.2360.27a 0.4560.06 0.54 60.11 1.09 60.24
LDL 5.7260.49b 3.0960.23 3.11 60.18 1.80 60.24b 3.8860.50
HDL 1.6160.18 1.06 60.11 1.22 60.15 0.76 60.13 1.53 60.26
LDP 0.0760.03 0.05 60.01 0.03 60.01 0.06 60.01 0.04 60.01
Data are mean 6 sem. Groups as in Table 1. Abbreviations are: TOT, total cholesterol; VLDL 1 IDL, a combination of very low-density and intermediate-
density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; LDP, lipoprotein-deficient plasma.
a P , 0.05 vs control
b P , 0.01 vs control
Table 3. Lipoprotein lysophosphatidylcholine (lmol/liter)Phospholipid composition of lipoproteins and the albu-
min-rich LDP fraction analyzed by thin-layer chromatog- NS-H NS-N CON NRD SNA
raphy. Phospholipids were extracted in a stepwise fash- N 8 7 6 8 6
TOTAL 364683 277 629 247 649 200 617 380 6121ion. First with a mixture of methanol (2.53 3 fraction
VLDL 1 IDL 56 623a 3367a 962 11 63 38 612avolume) and chloroform (1.27 3 fraction volume), then
LDL 95620a 6667a 3566 27 67 82 618a
with chloroform and water (both 1.27 3 fraction vol- HDL 9269 89 63 98 616 62 610 123614
LDP 2265a 1964a 46610 14 64a 3668ume). The chloroform fraction was then evaporated, and
the residue dissolved in 2 ml chloroform:methanol (2:1, Data are means 6 sem. Abbreviations are in Table 2.
a P , 0.05 vs. controlvol:vol). Phosphorus content was determined with a
modified Bartlett procedure [26]. Phospholipid species
were separated by thin-layer chromatography. An aliquot
containing 300 nmol phosphorus was evaporated, and
levels were markedly decreased in all groups (P , 0.01).the residue dissolved in 100 ml chloroform:methanol (2:1,
Cholesterol, phospholipids and triglycerides were all in-vol:vol) and spotted onto the plate. Separation of phos-
pholipid species was achieved using a solvent composed creased in the NS-H group and cholesterol was decreased
of chloroform:methanol:acetic acid:water (100:50:16:4, in NRD group. The median level of proteinuria was
vol:vol). Phospholipids were visualized with iodine, scraped similar in the three groups with renal disease (NS-H,
from the plate, and phosphorus content of the various NS-N and SNA).
species [lysophosphatidylcholine (LPC), sphingomyelin,
phosphatidylcholine and phosphatidylethanolamine] in Lipoprotein cholesterol
each lipoprotein was determined with the modified Bart-
VLDL 1 IDL-cholesterol level was significantlylett procedure [26].
higher than controls in both the NS-H and NS-N groups
(P , 0.05; Table 2). However, the NS-H group exhibitedStatistics
significantly higher LDL-cholesterol levels (P , 0.01),Results are expressed as means 6 sem. One-way
while cholesterol levels were significantly decreased inANOVA was used to evaluate the statistical significance
the NRD group (P , 0.05). No significant differencesbetween values obtained in different groups. If variance
were found in the other two groups (NS-N and SNA)ratios reached statistical significance, the difference be-
in comparison to control subjects.tween the means were analyzed with the posthoc tests
versus controls (Dunnett) for P , 0.05 and P , 0.01. If
data were not normally distributed, logarithmic transfor- Lipoprotein lysophosphatidylcholine
mation was applied. Lysophosphatidylcholine (LPC) is a phospholipid
which is derived from PC [3, 28, 29]. As can be seen in
Table 3, VLDL 1 IDL-LPC level was increased in theRESULTS
NS-H, NS-N and SNA groups (P , 0.05). The LDL-Characteristics of the subjects
LPC level were also significantly higher than CON inClinical characteristics of the different groups are
these groups (P , 0.05). In the NRD group, where LDLshown in Table 1. No statistically significant differences
cholesterol levels were low, LDL-LPC levels were notwere observed with respect to gender, age and plasma
increased. There were no significant differences in HDL-creatinine levels. Patients with nephrotic syndrome
LPC levels. Conversely, LPC levels were significantly(NS-H and NS-N), subnormal albumin (SNA), and non-
decreased in the albumin-rich LDP fraction in the NS-H,renal disease (NRD) had statistically lower levels of total
proteins compared to the controls (P , 0.05). Albumin NS-N, and NRD groups (P , 0.05). Significant increases
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of LPC in LDL is increased in most nephrotic subjects,
even when hypoalbuminemia is relatively mild (SNA
group). Thus, hypoalbuminemia in the presence of nor-
molipidemia or hyperlipidemia appears to have a specific
effect on lipoprotein LPC content. This effect is not
restricted to LDL, but also occurs in VLDL and IDL.
It is not clear why this does not take place in HDL, but
the resistance of HDL to the sequestration of LPC may
enable this particle to exert its anti-atherosclerotic effect
[34–36].
In human plasma, albumin is the most abundant pro-
Fig. 1. Lysophosphatidylcholine/cholesterol ratios in low-density lipo- tein with a normal concentration of approximately 40 g/
protein of hypoalbuminemic patients. Data are means 6 sem. Abbrevia- liter [37, 38]. It is highly soluble and binds a variety oftions are: NS-H, hyperlipidemic nephrotic syndrome; NS-N, normolipi-
exogenous (metals, drugs) and endogenous substancesdemic nephrotic syndrome; CON, control subjects; NRD, nonrenal
diseases; SNA, subnormal albumin. *P , 0.05 vs. control. (nonesterified fatty acids, bilirubin, amino acids and
LPC) [20, 38]. Previously it has been shown that hypoal-
buminemia of the nephrotic syndrome is accompanied
by an increase in the nonesterified fatty acid content ofin LDL LPC/cholesterol ratios were observed in the
lipoproteins [39, 40]. Presently, we have documentedNS-N and SNA groups (Fig. 1).
such an effect for the LPC content of lipoproteins. LPC
is formed out of PC by phospholipase A2 [4, 5, 27–29, 41]
DISCUSSION or as a product of the lecithin:cholesterol acyl transferase
reaction (LCAT) [42]. Phospholipase A2 is either associ-In hypoalbuminemic patients with proteinuria, with or
without hyperlipidemia, LPC was increased in VLDL 1 ated with lipoproteins [3–5] or secreted by platelets [43].
LCAT activity is enhanced in the nephrotic syndromeIDL and LDL. Conversely, in all hypoalbuminemic pa-
tients LPC was decreased in lipoprotein-deficient [24, 44]. Both phospholipase A2 and LCAT transfer fatty
acids from the sn-2 position of phosphatidylcholine [5,plasma, the albumin-containing fraction. These findings
suggest that in the presence of hypoalbuminemia and 30, 41, 42] resulting in the formation of LPC. Irrespective
of its route of formation, LPC is always transferable toeither normolipidemia or hyperlipidemia, LPC shifts
from albumin to VLDL, IDL and LDL. albumin [45]. Previously, albumin has been identified as
an antioxidant [46–49]. Whether this is due to bindingIncreased LPC levels in LDL are commonly associated
with oxidation in vitro. The LPC level can be increased of transition metals [38, 48, 49], LPC, or both is unclear.
Irrespective of the exact nature of its antioxidant effect,6- to 30-fold depending on the degree of oxidation [6,
7, 10, 24, 29, 30]. Previously, it has been found that in it is well known that incubation of oxidized lipoproteins
with albumin can reverse their deleterious effects oncirculating LDL, LPC levels are much less variable [23,
29], which probably reflects the effectiveness of antioxi- endothelial function [6, 10, 50, 51]. Hence, it follows that
in vivo albumin also has such an effect. Presumably thisdative defense mechanisms in the circulation. Some in-
creases in LDL LPC content have been identified in function is proportionally reduced under hypoalbumi-
nemic circumstances.patients with dyslipidemia due to diabetes [16, 17], or
familial hypercholesterolemia [18]. These increases may In hypoalbuminemia, increased LPC levels in circulat-
ing LDL will probably cause effects that resemble thosebe due to a prolonged half-life [31] or increased oxidative
stress [32]. However, the increase in LPC content was caused by oxidized LDL, albeit to a lesser degree.
Whether the increased LPC levels in VLDL and IDLonly 40% [10, 33], consistently less than the nearly two-
fold increase that we found in LDL of normolipidemic, also have deleterious effects on endothelial function is
not clear, but evidence is accumulating that triglyceride-hypoalbuminemic subjects in the present study, in whom
lipoprotein metabolism was probably not grossly abnor- rich particles [34, 52] and their cholesterol-rich remnants,
primarily IDL [34], have pro-atherosclerotic effects. Re-mal. Moreover, in the presence of hyperlipidemia, the
increase in LPC in LDL was nearly threefold in the cent data from the MARS study underscore the potential
relevance of IDL for progression of atherosclerotic dis-hypoalbuminemic nephrotic patients. However, per
mmol cholesterol LDL LPC levels were not significantly ease [53]. Indeed, we recently found a correlation be-
tween the reduction of IDL cholesterol and the level ofincreased in these patients. Whether this implies that
LDL particle size was larger in the hyperlipidemic than improvement of endothelial function in patients with
combined hyperlipidemia [54]. Thus, LPC accumulationin the normolipidemic nephrotic patients, and that there
were relatively more LDL particles in the normolipi- in VLDL and IDL may also not be innocuous.
Albumin-binding leads to a decrease in the transferdemic patients is not certain. Nevertheless, the total load
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line in oxidized low-density lipoprotein in cultured vascular endo-of LPC from oxidized LDL to other compartments such
thelial cells. Circ Res 71:614–619, 1992
as the endothelial or red cell membrane. It has been 7. Sugiyama S, Kugiyama K, Ohgushi M, Fujimoto K, Yasue H:
Lysophosphatidylcholine in oxidized low-density lipoprotein in-shown that albumin can reduce the uptake of LPC by
creases endothelial susceptibility to polymorphonuclear leukocyte-cultured endothelial cells [27]. The consequence is less
induced endothelial dysfunction in porcine coronary arteries. Role
LPC-induced suppression of endothelium-dependent ar- of protein kinase C. Circ Res 74:565–575, 1992
8. Jessup W: Oxidized lipoproteins and nitric oxide. Curr Opinionterial tone [10]. Thus, it is not inconceivable that during
Lipid 7:274–280, 1996hypoalbuminemia, endothelial function will be disturbed
9. Esterbauer H, Gebicki J, Puhl H, Ju¨rgens G: The role of lipid
due to a quantitative increase in the amount of mem- peroxidation and antioxidants in oxidative modification of LDL.
Free Radic Biol Med 13:341–390, 1992brane-bound LPC. It is also well-known that there is
10. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD:rapid exchange of LPC between red cell membranes
Impairment of endothelium-dependent arterial relaxation by lyso-
and either albumin [55] or lipoproteins [56]. Indeed, we lecithin in modified low-density lipoproteins. Nature 344:160–162,
1990found that red cells in analbuminemic rats showed a
11. Ohara Y, Peterson TE, Zheng B, Kuo JF, Harrison DG: Lyso-marked increase in LPC content with a concomitant re-
phosphatidylcholine increases vascular superoxide anion produc-
duction in deformability. These changes could be nor- tion via protein kinase C activation. Arterioscler Thromb 14:1007–
1013, 1994malized by the addition of albumin [57]. Most probably
12. Zembowicz A, Jones SL, Wu KK: Induction of cyclooxygenase-2this effect will also be present in hypoalbuminemic hu-
in human umbilical vein endothelial cells by lysophosphatidylcho-
mans, and may contribute to the increased risk of athero- line. J Clin Invest 96:1688–1692, 1995
13. Berkenboom G, Langer I, Carpentier Y, Grosfils K, Fontainesclerosis present in hypoalbuminemic patients with the
J: Ramipril prevents endothelial dysfunction induced by oxidizednephrotic syndrome [58]. Even in hypolipidemic subjects
low-density lipoproteins: A bradykinin-dependent mechanism. Hy-
with NRD, hypoalbuminemia may have resulted in a pertension 30:371–376, 1997
14. Ohgushi M, Kugiyama K, Fukunaga K, Murohara T, Sugiyamashift of LPC from albumin to nonlipoprotein compart-
S, Miyamoto E, Yasue H: Protein kinase C inhibitors preventments.
impairment of endothelium-dependent relaxation by oxidatively
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Brain Res 45:317–320, 1997
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diabetes after intensive insulin therapy. Arteriosclerosis 10:232–tionate increase in cardiovascular disease in nephrotic
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